What Restandol Treats: Main Uses and Benefits

Restandol (Testosterone Undecylate) is primarily used in Androgen Replacement Therapy (ART) in situations involving the management of a clinically documented deficiency of the essential male hormone, testosterone, a condition commonly known as male hypogonadism. This medication is applied when the body's natural production of the hormone is insufficient. The primary therapeutic applications are commonly used in the management of conditions characterized by primary hypogonadism, hypogonadotropic hypogonadism, and late-onset hypogonadism (LOH).

The therapy provides supportive relief by addressing the functional deficits that cluster around the physical, sexual, and psychological domains. The primary therapeutic applications are commonly used in the management of conditions characterized by primary hypogonadism, hypogonadotropic hypogonadism, and late-onset hypogonadism (LOH). Patients may experience support for a range of symptoms, including low libido, erectile dysfunction, reduced muscle mass, chronic fatigue, and difficulties with concentration. This symptomatic assistance is relevant for easing the overall symptom load, which supports a sense of well-being during symptomatic periods when symptoms interfere with routine activities.

The eligibility for Restandol (Testosterone Undecanoate) is strictly governed by official regulatory guidelines, limiting its use to a specific patient population.

Contraindications (Must Not Use)

The medicine is absolutely contraindicated in all women, especially those who are pregnant or breastfeeding. It must not be used by men with known or suspected carcinoma of the prostate or carcinoma of the male breast. Patients with a history of liver tumors or a known hypersensitivity to any of the ingredients are also excluded.

Use Restrictions and Special Caution

Restandol is approved only for adult males with clinically confirmed hypogonadism. Its safety and efficacy have not been established in children or adolescents (under 18 years). Use is not recommended for men with low testosterone caused by age-related factors alone. Special caution and close monitoring are required for patients with pre-existing cardiac, renal, or hepatic disease, or uncontrolled hypertension, due to the risk of fluid retention and blood pressure increases.

Officially documented interactions for Restandol (Testosterone Undecylate) relate to pharmacodynamic and exposure-modifying effects on co-administered medications, as detailed in governmental regulatory labeling. No drug-drug combinations are explicitly listed as absolute contraindications in the interaction sections of major regulatory documents.

The official interaction profile is structured by requirements for clinical monitoring and dose management due to these interactions. Additionally, a crucial drug-food interaction is documented, requiring the medication to be administered with food as a mandatory condition for achieving adequate systemic exposure. This caution regarding fluid retention is also noted to be heightened for patients with pre-existing cardiac, renal, or hepatic disease.

Restandol, which contains testosterone undecanoate, functions as a pro-drug. Following absorption via the intestinal lymphatic system, it enters the systemic circulation and is then metabolized by endogenous non-specific esterases to yield the active hormone, testosterone.

Testosterone is a lipophilic molecule that acts as an agonist for the androgen receptor (AR), a ligand-dependent nuclear transcription factor expressed in diverse tissues including muscle, bone, and adipose tissue. Upon binding to testosterone, the AR dissociates from heat shock proteins, undergoes a conformational change, and translocates into the cell nucleus.

Once nuclear, the activated AR-ligand complex binds to specific Androgen Response Elements (AREs) in the genome, which are regulatory regions of target genes. This binding event modulates gene transcription, altering the rate of protein synthesis and expression profiles of numerous proteins. This genomic pathway results in systemic physiological modulation that sustains anabolism, regulates erythropoiesis, and maintains secondary sexual characteristics.

Restandol® Testocaps (testosterone undecanoate) is an oral testosterone replacement therapy used only in adult males with confirmed hypogonadism, which is characterized by clinically low testosterone levels on two separate morning blood measurements.

Administration Instructions

To ensure proper absorption of the active substance, the capsules must be taken with a normal meal. They should be swallowed whole with some water or fluid, without chewing. The total daily dosage is typically divided and taken in two doses (morning and evening). If the number of capsules to be taken daily is uneven, the larger dose should generally be taken in the morning.

Dosing Regimen

The dosage is highly individualized and determined by a healthcare provider based on the clinical effect and monitored serum testosterone levels.

Monitoring and Follow-up

Regular medical supervision is required throughout treatment. Monitoring typically involves blood tests to check serum testosterone and hemoglobin levels, as well as a digital rectal examination (DRE) of the prostate and Prostate-Specific Antigen (PSA) blood tests, particularly in elderly men. Do not adjust the prescribed dose or stop treatment without consulting your doctor.

Restandol: Recent Clinical Evidence

Evidence for Use in Hypogonadism

Research examined the use of oral testosterone undecylate in adult males with a confirmed diagnosis of male hypogonadism, a condition associated with low testosterone levels. The evidence base includes Randomized Controlled Trials (RCTs) against placebo, alongside systematic reviews and meta-analyses that explore data from multiple studies. The main focus of this research examined whether the oral formulation was associated with changes in serum total testosterone concentrations. Findings describe the patterns observed in the studies related to these hormonal changes. Comparative evidence against many other existing testosterone formulations is limited, and studies have largely focused on comparisons versus a placebo or non-treatment control.

Studies on Symptomatic and Functional Changes

Research explored how the medication was associated with changes across several key patient-reported outcomes describing perceived discomfort. Studies primarily monitored outcomes related to systemic or functional imbalance, including measures of body composition (lean mass and fat mass) and scores for sexual function and depressed mood. Some trials also explored whether the compound was observed in some studies to correlate with changes in bone mineral density (BMD). For certain functional outcomes, such as cognitive function and energy levels, the findings were mixed across different studies.

Long-Term Data and Uncertainties

The core efficacy trials were often conducted over short-term periods, typically lasting six months to one year. Long-term effects are not fully established, as the follow-up durations were limited for many foundational studies. Certainty remains low regarding the long-term persistence of measured change. Additionally, data for certain groups, such as males less than 18 years old, remain insufficient, and the overall evidence quality varies across studies.

How to Store and Dispose of Restandol (Testocaps)

Official regulatory information mandates specific conditions for storing and disposing of this medicine.

Storage Requirements

Disposal Instructions

To protect the environment, unused or expired Restandol must not be thrown away via wastewater or household waste. Patients are instructed to return the medicine to a pharmacy for proper disposal, ensuring compliance with local requirements for pharmaceutical waste.